This site is intended for US healthcare professionals only | Patients and Caregivers

  • Why Iluvien
    • Clinical Need
    • Continuous Microdosing
    • Pivotal Studies
    • Safety Data
  • Using Iluvien
    • Iluvien Patient Selection
    • Administration
  • Real-World Experience
    • Real-World Efficacy
    • Real-World Safety
    • Case Studies
    • Patient Testimonials
  • Resources and Support
    • AccessPlus Reimbursement
    • Patient Financial Support
    • Physician Educational Videos
    • Patient Educational Materials
    • Podcasts
  • Get Iluvien
  • Important Safety Information
  • Full Prescribing Information
  • Contact Us
Logo

 

Contact Form

To contact us for any reason, please fill in the form on this page.

  • This field is for validation purposes and should be left unchanged.

Customer Support

Tel: +1 844 445 8843

Email: customerservice@alimerasciences.com

Social Media


AccessPlus

Tel: +1 844 445 8843
Summary Overview of AccessPlus

Adverse event reporting,
medical inquiry, product returns or replacements

Tel: +1 844 445 8843

Fax: +1 678 990 5743

Email: pvalimerasciences@alimerasciences.com

Indication

ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Important Safety Information

Contraindications
  • ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.
  • ILUVIEN is contraindicated in patients with glaucoma who have cup to disc ratios of greater than 0.8.
  • ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product.
Warnings and Precautions
  • Intravitreal injections, including those with ILUVIEN, have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the intravitreal injection.
  • Use of corticosteroids including ILUVIEN may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or
    viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.
  • Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant
    migration into the anterior chamber.
Adverse Reactions
  • In controlled studies, the most common adverse reactions reported were cataract development (ILUVIEN 82%;
    sham 50%) and intraocular pressure elevation of ≥ 10 mm Hg (ILUVIEN 34%; sham 10%).

Please see full Prescribing Information.

  • Privacy Policy
  • Prescribing Information
  • Terms and Conditions
  • Alimera Sciences, Inc. Website

This site is intended for US residents only. Copyright © 2021 Alimera Sciences, Inc. All rights reserved. CONTINUOUS MICRODOSING is a trademark and ILUVIEN is a registered trademark of Alimera Sciences, Inc.

US-ILV-MMM-0538 03/2020